HRSA – Talk Bio

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

2 weeks ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

1 year ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation

Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy

1 year ago talkbio0Tagged Dosage Forms, drug discount program, Health Policy, HRSA, Johnson & Johnson, Study models

340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing

Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS

1 year ago talkbio0Tagged 340B, CHARGE Syndrome, drug discount program, HHS, hospital payments, HRSA, Johnson and Johnson, Stelara

Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments